These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26540493)

  • 1. Trastuzumab and Cardiac Outcomes in Breast Cancer: A Story We Know by Heart?
    Milano G; Chamorey E; Ferrero JM
    JAMA Oncol; 2016 Jan; 2(1):21-2. PubMed ID: 26540493
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
    Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
    JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy.
    Upshaw JN; Finkelman B; Hubbard RA; Smith AM; Narayan HK; Arndt L; Domchek S; DeMichele A; Fox K; Shah P; Clark A; Bradbury A; Matro J; Adusumalli S; Carver JR; Ky B
    JACC Cardiovasc Imaging; 2020 Jan; 13(1 Pt 2):198-210. PubMed ID: 31542526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy.
    Yamashita K; Tanaka H; Hatazawa K; Tanaka Y; Sumimoto K; Shono A; Suzuki M; Yokota S; Suto M; Mukai J; Takada H; Matsumoto K; Minami H; Hirata KI
    Int J Cardiovasc Imaging; 2021 Jan; 37(1):197-205. PubMed ID: 32860123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
    Huang G; Zhai J; Huang X; Zheng D
    Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac dysfunction in cancer patients receiving paclitaxel.
    Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
    Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
    [No Abstract]   [Full Text] [Related]  

  • 7. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small benefits in trastuzumab-related cardiotoxicity.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
    [No Abstract]   [Full Text] [Related]  

  • 12. Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF.
    Watanabe N; Otsuka S; Sasaki Y; Yuasa T; Shimada K
    Breast Dis; 2015; 35(4):253-61. PubMed ID: 26518668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of trastuzumab in clinical practice.
    McArthur HL; Chia S
    N Engl J Med; 2007 Jul; 357(1):94-5. PubMed ID: 17611218
    [No Abstract]   [Full Text] [Related]  

  • 14. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
    Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
    Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
    Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
    Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
    Clifton GT; Peace KM; Holmes JP; Vreeland TJ; Hale DF; Herbert GS; Litton JK; Murthy RK; Lukas J; Peoples GE; Mittendorf Elizabeth A
    Clin Immunol; 2019 Apr; 201():48-54. PubMed ID: 30817999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
    Schneeweiss A; Chia S; Hickish T; Harvey V; Eniu A; Waldron-Lynch M; Eng-Wong J; Kirk S; Cortés J
    Eur J Cancer; 2018 Jan; 89():27-35. PubMed ID: 29223479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.